amiloride indications/contra

Stem definitionDrug idCAS RN
158 2609-46-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amiloride
  • amiloride hydrochloride
  • amiloride hydrochloride anhydrous
  • amiloride hydrochloride dihydrate
  • amiloride HCl
A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
  • Molecular weight: 229.63
  • Formula: C6H8ClN7O
  • CLOGP: 0.11
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 5
  • TPSA: 156.79
  • ALOGS: -2.57
  • ROTB: 1

Drug dosage:

DoseUnitRoute
10 mg O

Approvals:

DateAgencyCompanyOrphan
Oct. 5, 1981 FDA PADDOCK LLC

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 145.28 56.05 27 79 11267 3374486
Hyponatraemia 108.41 56.05 23 83 18336 3367417

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC C03DB01 CARDIOVASCULAR SYSTEM
DIURETICS
POTASSIUM-SPARING AGENTS
Other potassium-sparing agents
CHEBI has role CHEBI:35498 diuretic
FDA PE N0000008859 Decreased Renal K+ Excretion
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175418 Potassium-sparing Diuretic
MeSH PA D062646 Acid Sensing Ion Channel Blockers
MeSH PA D004232 Diuretics
MeSH PA D062686 Epithelial Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D026941 Sodium Channel Blockers

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Hypokalemia Prevention indication
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Acidosis contraindication 51387008
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:2527
Diabetic renal disease contraindication 127013003
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Azotemia contraindication 445009001
Hypercalcemia off-label use 66931009 DOID:12678
Nephrogenic diabetes insipidus off-label use 111395007 DOID:12387
Peripheral Edema due to Chronic Heart Failure off-label use
Pulmonary Edema due to Chronic Heart Failure off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.64 Basic
pKa2 4.41 Basic
pKa3 0.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amiloride-sensitive sodium channel, ENaC Ion channel BLOCKER IC50 6.70 CHEMBL CHEMBL
Acid-sensing ion channel 2 Ion channel BLOCKER IC50 4.60 IUPHAR
Amine oxidase [flavin-containing] A Enzyme IC50 5.41 DRUG MATRIX
Acid-sensing ion channel 3 Ion channel IC50 5.36 CHEMBL
Amiloride-sensitive sodium channel subunit alpha Ion channel IC50 6.11 CHEMBL
Acid-sensing ion channel 1 Ion channel IC50 5 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.24 CHEMBL
Sodium/hydrogen exchanger 1 Transporter IC50 4.22 CHEMBL
Adenosine receptor A2a GPCR Ki 5.48 WOMBAT-PK
Sodium/hydrogen exchanger 5 Unclassified INHIBITOR Ki 4.68 IUPHAR
Urokinase-type plasminogen activator Enzyme Ki 5.16 WOMBAT-PK
Sodium/hydrogen exchanger Unclassified IC50 4.01 CHEMBL
Membrane primary amine oxidase Enzyme Ki 5 CHEMBL

External reference:

scroll-->
IDSource
2421 IUPHAR_LIGAND_ID
4019603 VUID
N0000147699 NUI
C0002502 UMLSCUI
D00649 KEGG_DRUG
7DZO8EB0Z3 UNII
2352 INN_ID
2016-88-8 SECONDARY_CAS_RN
DB00594 DRUGBANK_ID
CHEMBL945 ChEMBL_ID
16231 PUBCHEM_CID
644 RXNORM
387503008 SNOMEDCT_US
87395005 SNOMEDCT_US
4019603 VANDF
N0000147699 NDFRT
N0000006772 NDFRT
004861 NDDF
d00169 MMSL
CHEBI:2639 CHEBI
CHEMBL1398126 ChEMBL_ID
D000584 MESH_DESCRIPTOR_UI
AMR PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Amiloride Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-117 TABLET 5 mg ORAL ANDA 11 sections
Amiloride Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 54868-0667 TABLET 5 mg ORAL ANDA 13 sections
AMILORIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 54868-5214 TABLET 5 mg ORAL NDA 12 sections
Amiloride Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60429-275 TABLET 5 mg ORAL ANDA 11 sections
Amiloride Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 64980-151 TABLET 5 mg ORAL ANDA 18 sections
Amiloride Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68151-0162 TABLET 5 mg ORAL ANDA 11 sections